Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel

Axicabtagene lisoleucel (Axi-cel) is the second approved gene-alterating cancer treatment and the first in aggressive lymphoma using the “chimeric antigen receptor” (CAR) technology. T-cells from patients were transfected with CARs and reinfused after a lymphodepleting chemotherapy. CAR T-cells are...

Descripción completa

Detalles Bibliográficos
Autores principales: Viardot, Andreas, Wais, Verena, Sala, Elisa, Koerper, Sixten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489634/
https://www.ncbi.nlm.nih.gov/pubmed/31114317
http://dx.doi.org/10.2147/CMAR.S163225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489634/
https://www.ncbi.nlm.nih.gov/pubmed/31114317
http://dx.doi.org/10.2147/CMAR.S163225

Ejemplares similares